Stock DXB DIMERIX LIMITED
Add to a list

Dimerix Limited Stock

Stocks

DXB

AU000000DXB7

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - Australian S.E.
Other stock markets
 10:15:48 28/07/2026 +04 		5-day change 1st Jan Change
0.2500 AUD +2.04% Intraday chart for Dimerix Limited +11.11% -54.55%
07-23 Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4% MT
07-17 Dimerix Limited and Mission Therapeutics Limited Expand Pipeline with Acquisition of Phase 2 Ready Asset for Acute Kidney Injury CI

Valuation: Dimerix Limited

Market Cap 123M 85.88M 75.37M 70.18M 64.55M 121M 8.2B 833M 326M 4.07B 322M 315M 14.06B P/E 2024
-13.5x
P/E 2025 -24.3x
Enterprise Value 54.9M 38.3M 33.61M 31.3M 28.79M 53.97M 3.66B 371M 145M 1.81B 144M 141M 6.27B EV / Sales 2024
443x
EV / Sales 2025 49.4x
Free-Float
77.77%
Yield 2024 *
-
Yield 2025 -
* Estimated data More valuation ratios

Chart: Dimerix Limited

Dynamic Chart

Latest news : Dimerix Limited

07-23 Dimerix Secures US Patent Regarding Kidney Injury Drug Candidate, Shares Jump 4% MT
07-17 Dimerix Limited and Mission Therapeutics Limited Expand Pipeline with Acquisition of Phase 2 Ready Asset for Acute Kidney Injury CI
07-17 Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says MT
07-17 Dimerix Acquires Therapeutic Asset from UK-Based Firm; Shares Up 8% MT
07-17 Dimerix Secures AU$10 Million Loan Facility From Substantial Shareholder Associate; Shares Up 9% MT
07-09 Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients MT
06-17 Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says MT
06-16 Dimerix Limited Licenses Exclusive Rights to Everest Medicines to Commercialise Dmx-200 in Greater China, South Korea and Southeast Asia CI
06-16 Everest Medicines Secures Rights to Dimerix's Kidney Disease Drug in Asia MT
06-16 Dimerix Signs Exclusive License Agreement for DMX-200 in Greater China, South Korea, Southeast Asia, Shares Surge 18% MT
05-01 Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says MT
04-28 Dimerix Limited Announces Completion of Blinded Assessment of ACTION3 Statistical Assumptions CI
04-28 Dimerix Says Phase 3 Clinical Trial Data Review Shows Over 90% Statistical Power to Detect Proteinuria Treatment Effect; Shares Reach Two-Year Low MT
More news

Analysts' recommendations: Dimerix Limited

07-17 Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says MT
06-17 Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says MT
05-01 Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says MT
04-14 Dimerix Poised to Benefit From US FDA's Approval of Travere Therapeutics' Kidney Disorder Drug, Euroz Hartleys Says MT
04-08 Dimerix Sees No Impact From US Pharma Tariffs, Says Euroz Hartleys MT
More recommendations

Press Releases: Dimerix Limited

07-17 Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline AQ
06-17 Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia AQ
01/05/25 Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States AQ
05/10/23 ADVANZ PHARMA and Dimerix enter into an Exclusive License Agreement to commercialise DMX-200 in Europe, Canada, Australia, and New Zealand AQ
27/07/22 Dimerix : Quarterly Appendix 4C and Activities Report PU
More press releases

Quotes and Performance

1 day+2.04%
1 week+11.11%
Current month+21.95%
1 month+31.58%
3 months-35.90%
6 months-52.38%
Current year-54.55%
More quotes

Course Extremes

1 week 0.23
Extreme 0.23
 0.26
1 month 0.2
Extreme 0.195
 0.27
Current year 0.16
Extreme 0.157
 0.56
1 year 0.16
Extreme 0.157
 0.66
3 years 0.06
Extreme 0.061
 0.78
5 years 0.05
Extreme 0.052
 0.78
10 years 0.05
Extreme 0.052
 0.78
More quotes

Managers and Directors: Dimerix Limited

Manager TitleAgeSince
Nina Webster CEO
 Chief Executive Officer - 27/08/2018
Michael Tonroe DFI
 Director of Finance/CFO 59 29/01/2026
David Fuller CTO
 Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Sonia Maria Poli BRD
 Director/Board Member 61 03/07/2015
Hugh Alsop CHM
 Chairman - -
Nina Webster BRD
 Director/Board Member - 27/08/2018
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
12/12/25
Sonia Maria Poli
Free

Director

100,000 0.0167%
12/12/25
Sonia Maria Poli
Free

Director

100,000 0.0167%
12/12/25
Nina Webster
Free

Chief Executive Officer

1,500,000 0.2498%
Transaction History

Other Biotechnology & Medical Research

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
DIMERIX LIMITED Stock Dimerix Limited
+2.04%+11.11%-55.75%+262.32% 103M
LONZA GROUP AG Stock Lonza Group AG
+0.14%-0.67%-0.88%+11.02% 47.74B
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
-3.12%-0.10%+391.44%+612.21% 39.98B
BEONE MEDICINES AG Stock BeOne Medicines AG
+0.59%+2.87%+11.32%+45.62% 36.23B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+12.13%+18.80%+21.12%+5.92% 35.59B
CELLTRION, INC. Stock Celltrion, Inc.
-0.73%+2.78%+4.65%+41.16% 27.91B
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
-2.10%-2.73% - - 16.71B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-1.34%+9.80%+28.85%+129.10% 16.45B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
+2.39%-1.64%+4.74%+9.95% 13.21B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.93%+8.81%-4.41%-28.09% 12.93B
Average +1.72%+3.39%+44.56%+121.02% 24.69B
Weighted average by Cap. +1.60%+2.96%+75.49%+130.07%
See all sector performances

Financials

2024 2025
Net sales 583K 407K 357K 333K 306K 574K 38.89M 3.95M 1.54M 19.29M 1.53M 1.5M 66.64M 5.59M 3.9M 3.42M 3.19M 2.93M 5.49M 372M 37.79M 14.79M 185M 14.63M 14.32M 638M
Net income -17.08M -11.91M -10.46M -9.74M -8.96M -16.79M -1.14B -116M -45.21M -564M -44.73M -43.76M -1.95B -13.25M -9.25M -8.11M -7.56M -6.95M -13.03M -883M -89.65M -35.09M -438M -34.71M -33.96M -1.51B
Net Debt -21.99M -15.34M -13.47M -12.54M -11.53M -21.62M -1.47B -149M -58.23M -727M -57.61M -56.36M -2.51B -68.19M -47.58M -41.75M -38.88M -35.76M -67.04M -4.55B -461M -181M -2.25B -179M -175M -7.79B
* Estimated data More financial data

Company Profile

Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
28/07/26 A$0.2500 +2.04% 2,169,136
27/07/26 A$0.2450 -2.00% 265,681
24/07/26 A$0.2500 +4.17% 1,091,226
23/07/26 A$0.2400 -4.00% 2,448,999
22/07/26 A$0.2500 +8.70% 1,986,809

Delayed Quote Australian S.E.

More quotes

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. DXB Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong